Wright Petitions FDA To Deny Smith & Nephew’s Hip Resurfacing PMA
This article was originally published in The Gray Sheet
Executive Summary
Approval of Smith & Nephew's PMA for its Birmingham hip resurfacing system would set a "dangerous precedent," orthopedic competitor Wright Medical contends in written comments to FDA
You may also be interested in...
Wright Looks To New Management, Hip Resurfacing To Get Back On Track
Wright Medical Group believes a change in its management and release of the Conserve Plus hip resurfacing system could reverse the firm's recent sales slide
Wright Looks To New Management, Hip Resurfacing To Get Back On Track
Wright Medical Group believes a change in its management and release of the Conserve Plus hip resurfacing system could reverse the firm's recent sales slide
Panel Supports Smith & Nephew’s Birmingham Hip Resurfacing System
FDA's Orthopaedic & Rehabilitation Devices Panel narrowly recommended approval for Smith & Nephew's Birmingham Hip Resurfacing system Sept. 8, provided that the firm conducts a postmarket study